ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Princess Margaret Cancer Centre at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Princess Margaret Cancer Centre takes part in 23 sessions at ESMO 2026 in Madrid. Its program covers treatment and care across several cancers, with a focus on lung and ovarian cancer. Specific topics include treatment options for lung cancers with ROS1 gene changes and biomarkers linked to treatment response in platinum-resistant ovarian cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Princess Margaret Cancer Centre Toronto, Canada | |
Cancer hospital of University Health Network in Toronto, Canada, affiliated with the University of Toronto. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 BRCA functional domain mutations as predictive biomarkers for PARP inhibitor benefit in ovarian cancer: A systematic review and meta-analysis Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Thromboembolic events in non-small cell lung cancer with rare oncogenic driver mutations Lung & thoracic cancers Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Talk Fri Oct 23 13:30–13:50 Presentation by Expert Lung & thoracic cancers Chair Fri Oct 23 13:30–14:30 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Chair Sat Oct 24 08:30–10:00 Challenges in the treatment approach of HPV-related head and neck cancers Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 08:57–09:02 Talk Sat Oct 24 09:30–09:50 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Quality-adjusted survival with PARP inhibitor maintenance in platinum-responsive ovarian cancer: A systematic review and meta-analysis Gynaecological cancersNursing & supportive care Talk Sat Oct 24 19:00–19:15 Unmet needs: Breakthroughs in first line systemic therapies for HER2+ disease Gastrointestinal cancersBiomarkers & precision oncology Talk Sun Oct 25 10:20–10:40 The role of medical oncologist Sarcoma, CNS, head & neck and rare cancers Poster Sun Oct 25 12:00–12:45 Abstract Sun Oct 25 17:06–17:18 Invited Discussant LBA6 Lung & thoracic cancersGastrointestinal cancers Talk Sun Oct 25 19:05–19:25 Established therapeutic algorithms for patients with ROS1-fused advanced NSCLC Lung & thoracic cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Germline genetic variants associated with VTE risk in patients with ALK, ROS-1 and other rare mutations in non-small cell lung cancer (NSCLC) Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Serial tumor-naïve cfDNA MRD detection predicts recurrence in pleural mesothelioma: Insights from the SMARTEST trial Lung & thoracic cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 The impact of pimicotinib on quality of life (QoL) in patients with tenosynovial giant cell tumour (TGCT): EQ-5D-5L findings from the phase 3 MANEUVER trial Sarcoma, CNS, head & neck and rare cancersNursing & supportive care Talk Mon Oct 26 17:15–17:35 Anxiety and death anxiety Nursing & supportive care |
Find decision makers at Princess Margaret Cancer Centre
Tell us what you sell and we’ll find the people at Princess Margaret Cancer Centre most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction